Therefore, anti-IgE therapy was shown to prevent viral exacerbations of asthma (66) and the exacerbation number was reduced even when omalizumab was given 4–6 weeks before children return to school in fall, especially in those who had recently experienced an asthma attack (67). The gene discussed is IGHE; the disease is asthma.